Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;77(2):253-265.
doi: 10.1007/s00018-019-03268-1. Epub 2019 Aug 29.

Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis

Suja Ann Mathew  1 , Charuta Naik  2 , Paul A Cahill  3 , Ramesh R Bhonde  4
Affiliations
Review

Placental mesenchymal stromal cells as an alternative tool for therapeutic angiogenesis

Suja Ann Mathew et al. Cell Mol Life Sci. 2020 Jan.

Abstract

Dysregulation of angiogenesis is a phenomenon observed in several disorders such as diabetic foot, critical limb ischemia and myocardial infarction. Mesenchymal stromal cells (MSCs) possess angiogenic potential and have recently emerged as a powerful tool for cell therapy to promote angiogenesis. Although bone marrow-derived MSCs are the primary cell of choice, obtaining them has become a challenge. The placenta has become a popular alternative as it is a highly vascular organ, easily available and ethically more favorable with a rich supply of MSCs. Comparatively, placenta-derived MSCs (PMSCs) are clinically promising due to their proliferative, migratory, clonogenic and immunomodulatory properties. PMSCs release a plethora of cytokines and chemokines key to angiogenic signaling and facilitate the possibility of delivering PMSC-derived exosomes as a targeted therapy to promote angiogenesis. However, there still remains the challenge of heterogeneity in the isolated populations, questions on the maternal or fetal origin of these cells and the diversity in previously reported isolation and culture conditions. Nonetheless, the growing rate of clinical trials using PMSCs clearly indicates a shift in favor of PMSCs. The overall aim of the review is to highlight the importance of this rather poorly understood cell type and emphasize the need for further investigations into their angiogenic potential as an alternative source for therapeutic angiogenesis.

Keywords: Cell based therapy; Clinical trials; Conditioned media; Differentiation potential; Exosomes; Hypoxia; Immunomodulation; Ischemia; Placental mesenchymal stem cells; Pregnancy; Regenerative medicine; Secretome; Stem cells; Vasculature; Wound healing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest in their study.

Figures

Fig. 1
Fig. 1
Sources of placental mesenchymal stromal cells. The anatomy of the human term placenta, depicting major regions from which placental mesenchymal stromal cells (MSCs) have been derived. The amniotic fluid and the placental membranes have not been depicted
Fig. 2
Fig. 2
Placental mesenchymal stromal cells and angiogenesis. Pictorial outline describing the different sources and properties of placenta-derived mesenchymal stromal cells (PMSCs). PMSCs can be primed to enhance their angiogenic potential. The cells or their secretome can be applied to promote angiogenesis
Fig. 3
Fig. 3
In vitro tube formation of placental mesenchymal stromal cells. PMSCs showing tube formation potential post-24 h culture on Matrigel
Fig. 4
Fig. 4
Possible mechanism of placental mesenchymal stromal cells contributing to angiogenesis. Possible mechanism behind the role of PMSCs mediating angiogenesis via direct de-differentiation or through its paracrine effects on effector cells such as the smooth muscle cells, endothelial cells and the pericytes in forming mature vessels
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sherwood LM, Parris EE, Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. - PubMed
    1. Cao Y, Langer R. A review of Judah Folkman’s remarkable achievements in biomedicine. Proc Natl Acad Sci. 2008;105(36):13203–13205. - PMC - PubMed
    1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–674. - PubMed
    1. Yin G, Liu W, An P, Li P, Ding I, Planelles V, et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther. 2002;5(5):547–554. - PubMed
    1. Zhang H, van Olden C, Sweeney D, Martin-Rendon E. Blood vessel repair and regeneration in the ischaemic heart. Open Heart. 2014;1(1):e000016. - PMC - PubMed

LinkOut - more resources

-